Skip to main content
Terug
Watch Compare

PDS Biotechnology Corp

Datakwaliteit: 83%
PDSB
NASDAQ Manufacturing Chemicals
€ 1,08
▲ € 0,01 (0,93%)
Marktkapitalisatie: 60,56 M
Prijs
€ 1,09
Marktkapitalisatie
60,56 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -27,75 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-271,48%
Onder sectorgemiddelde (-54,44%)
ROIC-99,04%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio2,09
Interest Coverage-5,91

Waardering

PE (TTM|NTM)
-1,76 | -2,01
Onder sectorgemiddelde (-1,49)
P/B Ratio6,41
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -1,8 -1,5
P/B 6,4 1,6
ROE % -271,5 -54,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,9
D/E — 0,3

Koersdoel Analisten

3 analisten
Buy
Huidig
€ 1,08
+594.4%
Koersdoel
€ 7,50
€ 3,00
€ 4,50
€ 15,00
Vooruitzicht
Forward K/W -2,01
Forward WPA -€ 0,54
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,54
-€ 0,77 – -€ 0,40
 0,0 3
FY2026 -€ 0,55
-€ 0,71 – -€ 0,45
 0,0 3

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,20 -€ 0,14 +30,0%
Q32025 -€ 0,20 -€ 0,19 +3,4%
Q22025 -€ 0,23 -€ 0,21 +10,0%
Q12025 -€ 0,25 -€ 0,21 +14,9%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -34,50 M
ROE -271,48% ROA -91,77%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -27,75 M
ROIC -99,04% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,09
Interest Coverage -5,91 Asset Turnover N/A
Working Capital 14,56 M Tangible Book Value 9,45 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,76 Forward P/E -2,01
P/B Ratio 6,41 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -45,83%
Market Cap 60,56 M Enterprise Value 34,36 M
Per Share
EPS (Diluted TTM) -0,74 Revenue / Share N/A
FCF / Share -0,50 OCF / Share -0,50
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 80,45%
SBC-Adj. FCF -32,48 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -34,50 M -37,61 M -42,94 M -40,85 M -16,92 M
EPS (Diluted) -0,74 -1,03 -1,39 -1,43 -0,66
Gross Profit — — — — —
Operating Income -31,54 M -36,32 M -43,05 M -41,67 M -21,44 M
EBITDA — — — — —
R&D Expenses 19,03 M 22,57 M 27,76 M 29,43 M 11,25 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 5,34 M 4,66 M 4,21 M 1,32 M —
Income Tax -1,17 M -869.169,0 -1,41 M -1,20 M -4,52 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 30,49 M 45,36 M 59,39 M 77,01 M 67,20 M
Total Liabilities 21,24 M 26,35 M 33,26 M 33,01 M 3,99 M
Shareholders' Equity 9,25 M 19,00 M 26,13 M 44,00 M 63,21 M
Total Debt — — — — —
Cash & Equivalents 26,71 M 41,69 M 56,56 M 73,82 M 65,24 M
Current Assets 28,25 M 45,05 M 59,06 M 76,48 M 66,84 M
Current Liabilities 9,48 M 17,09 M 13,63 M 9,82 M 3,76 M